Epithalon: The Famous Human Result Belongs to a Different Substance

Start with the thing almost every summary gets wrong.

Epithalamine is a bovine pineal gland extract. It is made from animal tissue and contains a mixture of peptides.

Epitalon — also written epithalon or epithalone — is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, abbreviated AEDG. It was synthesised on the basis of the amino acid composition of epithalamine.¹

So one is an extract. The other is a defined four-amino-acid molecule designed from it. They are related. They are not interchangeable. Studies of one are not evidence for the other.

This is the study behind the longevity reputation, and it is worth reading precisely.

A 12-year randomised clinical study ran in elderly patients with coronary disease and accelerated ageing of the cardiovascular system.²

The substance tested was epithalamine. The paper's own title calls it a pineal gland peptide preparation.²

The reported results are substantial. Long-term treatment decreased functional age and the degree of cardiovascular ageing. Exercise tolerance increased.²

After twelve years, the number of subjects who had died in the epithalamine group was 28% lower than in controls. Cardiovascular mortality was two-fold lower.²

The peptide has its own evidence, and the best-known piece of it is a cell experiment.

Researchers added epithalon to a culture of telomerase-negative human fetal fibroblasts. Telomerase rebuilds the protective caps on chromosome ends. Most adult body cells switch it off.³

They reported three things. Epithalon induced expression of the enzyme's catalytic subunit. It induced telomerase activity. And it produced telomere elongation.³ The authors read this as reactivation of the telomerase gene in body cells.

A companion paper reported that the peptide let cells divide past their usual limit.⁴ A 2025 review collects twenty-five years of laboratory, animal and computational work. It describes geroprotective and neuroendocrine effects, including an influence on melatonin synthesis.¹

4

amino acids in epithalon¹

28%

lower mortality — in the epithalamine study²

25

years of published study, reviewed in 2025¹

The telomerase work came from the St Petersburg Institute of Bioregulation and Gerontology.³ V. Kh. Khavinson is an author on the telomerase paper, on the cell-division paper and on the epithalamine study.³⁴²

This is the same pattern that runs through the other Russian-developed peptides here. It is not a reason to dismiss the work. It is a reason to notice something: a long reference list can still rest on one programme. Independent replication is what is missing.

The 2025 review is a useful counterweight, because it comes from a different institution and summarises the field rather than adding to it.¹

• Telomerase activity in cultured cells is not a lifespan result. The 2003 paper reports what happened in fibroblasts in a dish.³
• The human mortality data is the extract's. Any claim that epithalon has been shown to lower mortality in people is citing the wrong substance.²
• Longer telomeres are not automatically better. Telomerase reactivation is also a feature of many cancer cells. The published work does not resolve that question.
• Independent replication is thin. Most primary work traces to one programme.³⁴²